Differential dose-response to oral xemilofiban after antecedent intravenous abciximab: Administration for complex coronary intervention Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Benzamidines
  • Coronary Disease
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex

abstract

  • Both the magnitude and the duration of pharmacodynamic response to xemilofiban were enhanced by prior abciximab treatment. The potentiated pharmacodynamic response was not evident after 1 week. This observation has implications for the safety and efficacy of sequential parenteral-oral GP IIb/IIIa blockade therapy and may be useful in deriving dose regimens for orally administered compounds.

publication date

  • September 16, 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8790024

Additional Document Info

start page

  • 906

end page

  • 10

volume

  • 94

number

  • 5